NeuClone and Serum Institute of India (SIIPL) are developing 10 biosimilar antibody products for global commercialisation.

High quality, affordable biosimilars are made possible through NeuClone’s technology and Right from the Start® development approach, and SIIPL’s large scale biomanufacturing expertise.

NeuClone is responsible for initial biosimilar development while SIIPL is responsible for FDA/EMA compliant manufacture of finished product.

**PIPELINE PROGRESS AND OUTLOOK**
- HERCEPTIN biosimilar completed Phase I
- STELARA biosimilar undergoing Phase I
- PROLIA, PERJETA & SYNAGIS biosimilars ready to undergo, or have already started, process development and scale-up
- We seek commercialisation partners to contribute to the development and commercialisation of our products

**BIOSIMILARS, RIGHT FROM THE START®**
NeuClone implements a Right from the Start® approach to biosimilar development consisting of four attributes:

1. **RIGHT SEQUENCE:** Early focus on primary structure identification of originator through proprietary processes involving Peptide Mass Fingerprinting (PMF), intact mass and X-ray crystallography.
2. **RIGHT APPROACH:** Biosimilarity by Design™ approach based on QbD principles confirms biosimilarity from the earliest stages and throughout development to ensure quality is maintained downstream.
3. **RIGHT FUNCTIONALITY:** In-house development and testing of cell-based assays confirms biosimilar function in the native cellular environment
4. **RIGHT PRICE:** NeuClone’s NeuMAX® technology, incorporated at the start of development, allows for the low-cost manufacture of biosimilars and contributes to affordability and pricing flexibility.

**QUALITY, CAPACITY, COST**
- NeuClone ensures biosimilar quality downstream by focussing on the earliest and most risk intensive stages of development.
- SIIPL complements this with process experience and large cGMP manufacturing capacity for global supply.
- The NeuClone-SIIPL collaboration is aimed at becoming a cost leader in the global supply of FDA/EMA quality biosimilars.
- Lowest drug supply price globally allows partners to enter the market, at any stage, grow these markets and maintain ROI despite competitors.
- We encourage our licensing partners to propose a supply price and allow us to demonstrate our market-leading supply price commitment.
- In addition to the six disclosed, NeuClone has fourteen other biosimilar products in development and available for partnering.

**COMMERICAL OPPORTUNITY**

**THE MAJOR OPPORTUNITY IS THE DEVELOPED WORLD MARKETS**
- The current originator market is constrained in size by high price and limited product availability.
- NeuClone and SIIPL will expand the current originator market by providing affordable high-quality products to new patients.

**EMERGING BIOSIMILARS MARKET ALSO AN OPPORTUNITY**
- Emerging markets are constrained by price and availability of biologics and demand is estimated to be several fold greater than the current originator market in volume.

**NEUCLONE TECHNOLOGY**
- NeuClone’s NeuMAX® platform allows for the low cost manufacture of biologics and includes a proprietary vector system, medium and robust parental cell line.
- The parental cell line, NeuCHO®, delivers increased viable cell density and extends culture life, allowing for increased yields on harvest compared to standard CHO cells.
- Cell Expression System - US and Australian patent granted

**NEUCLONE & SIIPL**
- Pre-clinical toxicokinetics (TK)
- Phase I PK/PD clinical program

**NEUCLONE**
- Upstream development & biosimilar characterisation
- Initial process development
- Marketing rights to Developed World

**SIIPL**
- Process development and scale-up
- Clinical and commercial cGMP manufacture
- Marketing and distribution to RoW

---

GLOBAL RIGHTS TO RISK MANAGED BIOSIMILARS AT SCALE
UNIQUE DIFFERENTIATION THROUGH NEUCLONE AND SIIPL PARTNERSHIP

- Multiple biosimilar mAb products across various therapeutic classes available for global partnering.
- Simplified path to commercialisation as NeuClone and SIIPL take on all CAPEX and operating requirements of product manufacture.
- Industry leading team in upstream biologics development and analytics.
- Quality indistinguishable from originator based on Right from the Start® approach.
- As SIIPL has achieved as the world’s largest supplier of vaccines, they are committed to game-changing, disruptive supply pricing for biosimilar mAbs, and hence the global competitive landscape.
- NeuClone leverages the Australian R&D Tax Incentive scheme to reduce the cost of development by up to 41%.
- Serum Institute will supply FDA/EMA cGMP quality product below the supply pricing level possible by any current or projected future biosimilar supplier. SIIPL is committed to drive unique affordability.

WHO IS SIIPL?

WORLDWIDE LEADER IN BIOLOGICALS

- Largest manufacturer of vaccines globally (1.5b annually in 170 countries)
- 65% of the world’s children receive at least one SIIPL vaccine
- Produces over 50 vaccine products each with different production processes
- Experienced in all steps of scale-up, manufacture and formulation
- SIIPL aims to replicate its vaccine success with biosimilars through high-quality, affordable, large-scale production, for global supply

PROVEN BIOSIMILARS CAPACITY

- Successful scale-up to commercial volumes of biosimilar erythropoetin and a fully human rabies monoclonal antibody
- Clinical supply of HERCEPTIN and STELARA biosimilars

CONFORMING TO THE HIGHEST STANDARDS

- Compliance with US FDA and EMA requirements
- Facilities in Holland (EU certified), Czech Republic and India
- Large capacity with purpose built facility exclusively for NeuClone biosimilar mAbs

NC-SIIPL PIPELINE

<table>
<thead>
<tr>
<th>ORIGINATOR</th>
<th>EARLY PRECLINICAL</th>
<th>LATE PRECLINICAL</th>
<th>PROCESS SCALE-UP</th>
<th>PHASE I</th>
<th>PHASE III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herceptin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(trastuzumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stelara</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(ustekinumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolia/XGEVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(denosumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synagis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(palivizumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perjeta</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(pertuzumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humira</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(adalimumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(AS AT NOV 2019; 14 MORE PRODUCTS IN DEVELOPMENT)

SEEKING PRODUCT LICENSING AND CLINICAL DEVELOPMENT COLLABORATIONS

- Channel to global markets to maximise our long term commercial return
- Capacity and commitment to co-develop products globally
- Early engagement to allow coordinated design of clinical program

JOHN OKSINSKI HEAD OF GLOBAL BUSINESS DEVELOPMENT
MOBILE: +61 429 133 767
EMAIL: J.OKSINSKI@NEUCLONE.COM
COMMERCIAL IN CONFIDENCE